Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 142,690 shares of the medical research company's stock after selling 3,110 shares during the quarter. Calamos Advisors LLC's holdings in Thermo Fisher Scientific were worth $71,003,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. One Charles Private Wealth Services LLC grew its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock valued at $260,000 after buying an additional 20 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares in the last quarter. Holderness Investments Co. boosted its stake in Thermo Fisher Scientific by 1.7% during the fourth quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company's stock valued at $664,000 after buying an additional 21 shares during the last quarter. Port Capital LLC increased its stake in Thermo Fisher Scientific by 1.6% in the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after acquiring an additional 22 shares during the last quarter. Finally, Clark Capital Management Group Inc. boosted its position in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after acquiring an additional 23 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on TMO shares. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Barclays dropped their price target on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a research report on Tuesday, June 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Finally, Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $604.05.

Thermo Fisher Scientific Trading Up 0.1%

NYSE TMO traded up $0.49 during mid-day trading on Friday, hitting $428.25. The company's stock had a trading volume of 1,359,321 shares, compared to its average volume of 1,971,505. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The stock's fifty day simple moving average is $409.18 and its two-hundred day simple moving average is $479.90. The firm has a market capitalization of $161.66 billion, a P/E ratio of 25.12, a price-to-earnings-growth ratio of 2.28 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the business earned $5.11 earnings per share. The company's revenue was up .2% compared to the same quarter last year. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president owned 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.33% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.